Role of beta-blocker therapy in heart failure and atrial fibrillation

Cardiac Electrophysiology Review

Volumn 7, Issue 3, 2003, Pages 236-242

  Fung, Jeffrey W H ^a   Yu, Cheuk M ^a   Kum, Leo C C ^a   Yip, Gabriel W K ^a   Sanderson, John E ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atrial fibrillation; Beta blocker; Heart failure

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; METOPROLOL; PLACEBO; SOTALOL; SPIRONOLACTONE;

ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART PROARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; SINUS RHYTHM; STANDARDIZATION; SURVIVAL; SYMPTOMATOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; BISOPROLOL; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR FUNCTION, LEFT;

EID: 1342323677     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CEPR.0000012390.43937.2c     Document Type: Article

References (59)

1. American Heart Association. Heart and Stroke Statistical Update. Dallas: American Heart Association, 2002.
2. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-640.
3. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: A review of the literature. Int J Cardiol 2001;80:213-219.
4. Yip GW, Ho PP, Woo KS, Sanderson JE. Comparison of frequencies of left ventricular systolic and diastolic heart failure in Chinese living in Hong Kong. Am J Cardiol 1999;84:563-567.
5. Konstam MA. Progress in heart failure management? Lessons from the real world. Circulation 2000;102:1076-1078.
6. Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart failure improving? J Am Coll Cardiol 2000;36:2284-2286.
7. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-952.
8. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82:2N-9N.
9. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994;89:724-730.
10. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(Suppl VI);VI-102-VI-110.
11. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;334:493-498.
12. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
13. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D.
14. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32:695-703.
15. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimle A, Walden JA, Tillisch JH. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-1463.
16. Stevenson WG, Stevenson LW. Atrial Fibrillation in Heart Failure. N Engl J Med 1999;341:910-911.
17. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality. The Framingham Heart Study. Circulation 2003;107:2920-2925.
18. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: Clinical applications. JAMA 2002;287:890-897.
19. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
20. MERIT HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
21. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
22. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
23. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, Page RL. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001;142:498-501.
24. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-1433.
25. Fung JW, Chan SK, Yeung LY, Sanderson JE. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002;4:489-494.
26. Van den Berg MP, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: Current concepts and controversies. Heart 1997;77:309-313.
27. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997;78:564-568.
28. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-1794.
29. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
30. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, Clark A. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-387.
31. Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials update: Highlights of the scientific sessions of The American College of Cardiology, 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002;4:381-388.
32. Tse HF, Lau CP. Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation. J Am Coll Cardiol 2002;40:2150-2155.
33. Lau CP, Lok NS. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. Pacing Clin Electrophysiol 1997;20:2442-2452.
34. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-146.
35. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999;82:170-175.
36. Plewan A, Lehmann G, Alt E, Schmitt C. Maintenance of sinus rhythm after cardioversion of chronic atrial fibrillation: Sotalol versus bisoprolol. Eur Heart J 1999;20: 223.
37. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbæk J, Marchant B, Camm AJ, The Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction. N Engl J Med 1999;341:857-865.
38. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574-2579.
39. Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, In HH, Moon TH, Park GS, Cho SK. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: Randomized crossover study. Int J Cardiol 1995;52:167-174.
40. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: Mechanisms and clinical implications. Pacing Clin Electrophysiol 1996;19:95-106.
41. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Am J Med 1988;85:242-244.
42. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: Strategies to control, combat, and cure. Lancet 2002;359:593-603.
43. Solti F, Vecsey T, Kekesi V, Juhasz-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989;23:882-886.
44. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-283.
45. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999;100:87-95.
46. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002;105:2672-2678.
47. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: Results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-2581.
48. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-1161.
49. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction. Insight From the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003;107:2926-2931.
50. Fung JW, Yu CM, Yip GW, Chan S, Yandle TG, Richards, AM, Nicholls MG, Sanderson JE. Effect of Beta-blockade (Carvedilol or Metoprolol) on Activation of the Renin-Angiotensin-Aldosterone System and Natriuretic Peptides in Chronic Heart Failure. Am J Cardiol 2003;92:406-410.
51. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000;36:276-281.
52. Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J; MERIT-HF Study Group. Challenges of sub-group analyses in multinational clinical trials: Experiences from the MERIT-HF trial. Am Heart J 2001;142:502-511.
53. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292-296.
54. Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, Woo KS. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-1528.
55. Sanderson JE, Chan SK, Yu CM, Yeung LY, Chan WM, Raymond K, Chan KW, Woo KS. Beta blockers in heart failure: A comparison of a vasodilating beta blocker with metoprolol. Heart 1998;79:86-92.
56. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-1794.
57. Bristow MR. β-Adrenergic Receptor Blockade in Chronic Heart Failure. Circulation 2000;101:558-569.
58. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Lancet 2003;362:7-13.
59. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990;63:157-161.